Aethlon Medical Inc (AEMD) 8.1200 $AEMD
Aethlon Medical Announces Nasdaq Capital Market Listing Approval
PR Newswire - Wed Jul 08, 8:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's application to list its common stock on the Nasdaq Capital Market has been approved by The NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015 under its existing trading symbol, AEMD.
Aethlon Medical enters into USD6m equity investment agreement
M2 - Thu Jun 25, 6:06AM CDT
Biofiltration devices company Aethlon Medical (Other OTC:AEMD) revealed on Wednesday the launch of USD6m stock purchase agreement.
Aethlon Medical raises $6M in private placement
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 9:22AM CDT
Aethlon Medical Announces $6 Million Equity Investment
PR Newswire - Wed Jun 24, 7:07AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that it entered into a definitive $6 million stock purchase agreement. The per share purchase price was $6.30, which includes a five-year warrant that entitles the holder to purchase up to three common shares for each four shares purchased in the offering. The share purchase price underlying each warrant is also $6.30.
Aethlon Medical Discloses Upcoming Presentations
PR Newswire - Thu Jun 11, 8:05AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that its President Rod Kenley will give a presentation on June 12th at the 33rd Annual Vicenza Course on Critical Care Nephrology being held at the Fiera di Vicenza Convention Center in Vicenza Italy. Mr. Kenley's presentation is entitled, "A Case Study using Lectin-Affinity Plasmapheresis in the Treatment of Ebola Virus Disease." On June 16th, Mr. Kenley will be giving a presentation entitled, "Lectin-Affinity Plasmapheresis for the Extracorporeal Extraction of Pathogenic Viruses and Exosomes" at Goethe University in Frankfurt, Germany.
Aethlon Medical Announces Resignation of Inside Director to Comply with NASDAQ Corporate Governance Requirements
PR Newswire - Tue Jun 09, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that in order to support the Company's application to list on the Nasdaq Capital Market, Dr. Richard Tullis resigned from Aethlon's Board of Directors effective June 5, 2015. Under Nasdaq Corporate Governance Rule 5605(b), a listed company's Board of Directors is required to have a majority of independent directors. Prior to the resignation of Dr. Tullis, Aethlon's Board was comprised of an equal number of inside and outside directors. Dr. Tullis will continue in his position as the Company's Chief Science Officer.
Aethlon Medical to Present at the BIO International Convention
PR Newswire - Fri Jun 05, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that Chairman and CEO Jim Joyce will give a corporate presentation at the BIO International Convention on Thursday, June 18th in Philadelphia. The presentation is scheduled to begin at 10:00 AM ET in Theater 2 at the Pennsylvania Convention Center.
Aethlon Medical Expands Clinical Research Studies to Include Chikungunya Virus
PR Newswire - Thu Jun 04, 7:35AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that it has entered into an agreement with the National Institute of Virology (NIV) to begin testing of the Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating mosquito-borne virus that is not addressed with proven antiviral drug or vaccine therapies. In late 2013, Chikungunya was identified for the first time in the Americas on islands in the Caribbean. Since then, transmission of the virus has been identified in 44 countries or territories throughout the Americas with more than 1.2 million suspected cases reported to the Pan American Health Organization.
Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference
PR Newswire - Tue May 26, 8:15AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the SeeThruEquity 4th Annual Microcap Investor Conference on Thursday, May 28th. Details of Aethlon Medical's presentation are as follows:
SeeThruEquity Issues Update Note on Aethlon Medical, Inc. (OTCQB: AEMD)
ACCESSWIRE - Fri May 15, 8:01AM CDT
Update Note Focuses on Company's Announcement of Reverse Stock Split and Adjusts Target Price to $26.00
Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
PR Newswire - Wed May 13, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.
Aethlon Medical Announces Institutional Review Board Approval of Multi-Indication Cancer Study
PR Newswire - Tue May 12, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that the Institutional Review Board (IRB) of the University of California, Irvine (UCI) has approved a multi-indication clinical study entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment."
Aethlon Medical Announces Withdrawal of S-1 Registration Statement
PR Newswire - Mon May 04, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that on Friday, May 1, 2015, it filed with the Securities and Exchange Commission (the "SEC"
a request to withdraw its Registration Statement on Form S-1, File No. 333-203487, initially filed with the SEC on April 17, 2015. The Company requested to withdraw its Registration Statement due to market conditions and for broader strategic reasons.
Aethlon Medical Discloses Presentation of Preliminary CTE Related Study Results
PR Newswire - Thu Apr 16, 11:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that Dr. Robert Stern, professor of neurology, neurosurgery, and anatomy and neurobiology at Boston University School of Medicine (BUSM) has presented preliminary, unpublished findings related to research being conducted by Aethlon Medical's majority owned subsidiary, Exosome Sciences, Inc. The presentation was given earlier today at the 5th Annual Traumatic Brain Injury Conference being held in Washington, D.C.
Aethlon Medical Announces Cancer Clinical Trial Agreement
PR Newswire - Wed Apr 15, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has entered into an investigator-initiated clinical trial agreement with the University of California, Irvine (UCI). Under the agreement, a clinical study protocol entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment," will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The tumor types include the following forms of cancer; Breast adenocarcinoma, Colorectal, Gastric & Gastroesophageal, Pancreatic, Cholangiocarcinoma, Lung (NSCLC), Head & Neck (SCC), Melanoma and Ovarian adenocarcinoma. The principal investigator of the study is Edward Nelson, M.D.
Aethlon Medical Announces Effectiveness of Reverse Stock Split
PR Newswire - Tue Apr 14, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that its previously disclosed 1-for-50 reverse stock split is effective as of today, April 14, 2015, and that the Company's common stock will begin trading on a split-adjusted basis when the market opens today. The Company's common stock will trade on a split-adjusted basis under the temporary symbol "AEMDD," with the "D" appended to signify that the reverse stock split has occurred. The trading symbol will revert to "AEMD" after approximately 20 trading days.
Aethlon 1:50 reverse stock split effective today
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 6:01AM CDT
Aethlon Medical Announces Ebola Humanitarian Use Device Submission to the FDA
PR Newswire - Thu Apr 09, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has submitted a Humanitarian Use Device submission to the United States Food and Drug Administration (FDA) to support potential market clearance of the Aethlon Hemopurifier® as a treatment for Ebola virus. The Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and could serve as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
Aethlon Medical Announces Reverse Stock Split and Nasdaq Listing Submission
PR Newswire - Wed Apr 08, 6:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it will implement a 1-for-50 reverse split of its common stock. The implementation of the reverse stock split is subject to approval by the Financial Industry Regulatory Authority (FINRA). Upon approval by FINRA, the Company's common stock will trade on a split-adjusted basis under the temporary symbol "AEMDD," with the "D" appended to signify that the reverse stock split has occurred. The trading symbol will revert to "AEMD" after approximately 20 trading days. We currently anticipate that FINRA will approve the reverse stock split on April 10, 2015, however there can be no assurance that the effectiveness of the reverse stock split will occur on that date.
Aethlon Medical Discloses Head and Neck Cancer Collaboration
PR Newswire - Thu Apr 02, 7:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, disclosed today that its majority owned subsidiary Exosome Sciences, Inc. has entered into a research collaboration with Thomas Jefferson University. The goal of the collaboration is to advance a "liquid biopsy" that could improve the diagnoses and monitoring of head and neck cancer. In this regard, researchers will seek to determine whether exosome-based molecular signatures correlate with and predict patient responses to therapy.
Aethlon Medical Announces Nasdaq Capital Market Listing Approval
PR Newswire - Wed Jul 08, 8:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that the Company's application to list its common stock on the Nasdaq Capital Market has been approved by The NASDAQ Stock Market LLC. Aethlon's common stock is expected to begin trading on the Nasdaq Capital Market at the opening of market hours on Monday, July 13, 2015 under its existing trading symbol, AEMD.
Aethlon Medical enters into USD6m equity investment agreement
M2 - Thu Jun 25, 6:06AM CDT
Biofiltration devices company Aethlon Medical (Other OTC:AEMD) revealed on Wednesday the launch of USD6m stock purchase agreement.
Aethlon Medical raises $6M in private placement
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 9:22AM CDT
Aethlon Medical Announces $6 Million Equity Investment
PR Newswire - Wed Jun 24, 7:07AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that it entered into a definitive $6 million stock purchase agreement. The per share purchase price was $6.30, which includes a five-year warrant that entitles the holder to purchase up to three common shares for each four shares purchased in the offering. The share purchase price underlying each warrant is also $6.30.
Aethlon Medical Discloses Upcoming Presentations
PR Newswire - Thu Jun 11, 8:05AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that its President Rod Kenley will give a presentation on June 12th at the 33rd Annual Vicenza Course on Critical Care Nephrology being held at the Fiera di Vicenza Convention Center in Vicenza Italy. Mr. Kenley's presentation is entitled, "A Case Study using Lectin-Affinity Plasmapheresis in the Treatment of Ebola Virus Disease." On June 16th, Mr. Kenley will be giving a presentation entitled, "Lectin-Affinity Plasmapheresis for the Extracorporeal Extraction of Pathogenic Viruses and Exosomes" at Goethe University in Frankfurt, Germany.
Aethlon Medical Announces Resignation of Inside Director to Comply with NASDAQ Corporate Governance Requirements
PR Newswire - Tue Jun 09, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that in order to support the Company's application to list on the Nasdaq Capital Market, Dr. Richard Tullis resigned from Aethlon's Board of Directors effective June 5, 2015. Under Nasdaq Corporate Governance Rule 5605(b), a listed company's Board of Directors is required to have a majority of independent directors. Prior to the resignation of Dr. Tullis, Aethlon's Board was comprised of an equal number of inside and outside directors. Dr. Tullis will continue in his position as the Company's Chief Science Officer.
Aethlon Medical to Present at the BIO International Convention
PR Newswire - Fri Jun 05, 7:45AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, announced today that Chairman and CEO Jim Joyce will give a corporate presentation at the BIO International Convention on Thursday, June 18th in Philadelphia. The presentation is scheduled to begin at 10:00 AM ET in Theater 2 at the Pennsylvania Convention Center.
Aethlon Medical Expands Clinical Research Studies to Include Chikungunya Virus
PR Newswire - Thu Jun 04, 7:35AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, disclosed today that it has entered into an agreement with the National Institute of Virology (NIV) to begin testing of the Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating mosquito-borne virus that is not addressed with proven antiviral drug or vaccine therapies. In late 2013, Chikungunya was identified for the first time in the Americas on islands in the Caribbean. Since then, transmission of the virus has been identified in 44 countries or territories throughout the Americas with more than 1.2 million suspected cases reported to the Pan American Health Organization.
Aethlon Medical to Present at SeeThruEquity Microcap Investor Conference
PR Newswire - Tue May 26, 8:15AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that James A. Joyce, Chief Executive Officer, will present at the SeeThruEquity 4th Annual Microcap Investor Conference on Thursday, May 28th. Details of Aethlon Medical's presentation are as follows:
SeeThruEquity Issues Update Note on Aethlon Medical, Inc. (OTCQB: AEMD)
ACCESSWIRE - Fri May 15, 8:01AM CDT
Update Note Focuses on Company's Announcement of Reverse Stock Split and Adjusts Target Price to $26.00
Aethlon Medical Announces Health Canada Approval of Ebola Treatment Protocol
PR Newswire - Wed May 13, 8:30AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class affinity biofiltration device designed for the broad-spectrum elimination of viral pathogens from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other life-threatening viruses that are not addressed with proven drug therapies. Health Canada is the Federal department responsible for overseeing the health of Canadian citizens.
Aethlon Medical Announces Institutional Review Board Approval of Multi-Indication Cancer Study
PR Newswire - Tue May 12, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that the Institutional Review Board (IRB) of the University of California, Irvine (UCI) has approved a multi-indication clinical study entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment."
Aethlon Medical Announces Withdrawal of S-1 Registration Statement
PR Newswire - Mon May 04, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that on Friday, May 1, 2015, it filed with the Securities and Exchange Commission (the "SEC"
a request to withdraw its Registration Statement on Form S-1, File No. 333-203487, initially filed with the SEC on April 17, 2015. The Company requested to withdraw its Registration Statement due to market conditions and for broader strategic reasons. Aethlon Medical Discloses Presentation of Preliminary CTE Related Study Results
PR Newswire - Thu Apr 16, 11:01AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD, AEMDD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that Dr. Robert Stern, professor of neurology, neurosurgery, and anatomy and neurobiology at Boston University School of Medicine (BUSM) has presented preliminary, unpublished findings related to research being conducted by Aethlon Medical's majority owned subsidiary, Exosome Sciences, Inc. The presentation was given earlier today at the 5th Annual Traumatic Brain Injury Conference being held in Washington, D.C.
Aethlon Medical Announces Cancer Clinical Trial Agreement
PR Newswire - Wed Apr 15, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has entered into an investigator-initiated clinical trial agreement with the University of California, Irvine (UCI). Under the agreement, a clinical study protocol entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment," will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The tumor types include the following forms of cancer; Breast adenocarcinoma, Colorectal, Gastric & Gastroesophageal, Pancreatic, Cholangiocarcinoma, Lung (NSCLC), Head & Neck (SCC), Melanoma and Ovarian adenocarcinoma. The principal investigator of the study is Edward Nelson, M.D.
Aethlon Medical Announces Effectiveness of Reverse Stock Split
PR Newswire - Tue Apr 14, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that its previously disclosed 1-for-50 reverse stock split is effective as of today, April 14, 2015, and that the Company's common stock will begin trading on a split-adjusted basis when the market opens today. The Company's common stock will trade on a split-adjusted basis under the temporary symbol "AEMDD," with the "D" appended to signify that the reverse stock split has occurred. The trading symbol will revert to "AEMD" after approximately 20 trading days.
Aethlon 1:50 reverse stock split effective today
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 6:01AM CDT
Aethlon Medical Announces Ebola Humanitarian Use Device Submission to the FDA
PR Newswire - Thu Apr 09, 7:06AM CDT
Aethlon Medical, Inc. (OTCQB: AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it has submitted a Humanitarian Use Device submission to the United States Food and Drug Administration (FDA) to support potential market clearance of the Aethlon Hemopurifier® as a treatment for Ebola virus. The Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and could serve as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
Aethlon Medical Announces Reverse Stock Split and Nasdaq Listing Submission
PR Newswire - Wed Apr 08, 6:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that it will implement a 1-for-50 reverse split of its common stock. The implementation of the reverse stock split is subject to approval by the Financial Industry Regulatory Authority (FINRA). Upon approval by FINRA, the Company's common stock will trade on a split-adjusted basis under the temporary symbol "AEMDD," with the "D" appended to signify that the reverse stock split has occurred. The trading symbol will revert to "AEMD" after approximately 20 trading days. We currently anticipate that FINRA will approve the reverse stock split on April 10, 2015, however there can be no assurance that the effectiveness of the reverse stock split will occur on that date.
Aethlon Medical Discloses Head and Neck Cancer Collaboration
PR Newswire - Thu Apr 02, 7:05AM CDT
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, disclosed today that its majority owned subsidiary Exosome Sciences, Inc. has entered into a research collaboration with Thomas Jefferson University. The goal of the collaboration is to advance a "liquid biopsy" that could improve the diagnoses and monitoring of head and neck cancer. In this regard, researchers will seek to determine whether exosome-based molecular signatures correlate with and predict patient responses to therapy.
